UCSF has joined a growing network devoted to combating primary hyperoxaluria. As part of this initiative, patients can now ...

We can see that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) does use debt in its business. But is this debt a concern to shareholders? Debt assists a business until the business has trouble paying it ...

Detailed price information for Alnylam Pharmaceuticals (ALNY-Q) from The Globe and Mail including charting and trades.

Alnylam Pharmaceuticals (ALNY) shows strong price momentum, hitting new all-time highs on Aug. 11. ALNY has a 100% technical “Buy” opinion via Barchart. The company boasts a robust pipeline, recent ...

Company to Webcast Investor Event on August 30, 2025, at 1:00 p.m. EDT (7:00 pm CEST)- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that ...

In the assessment of 12-month price targets, analysts unveil insights for Alnylam Pharmaceuticals, presenting an average target of $420.41, a high estimate of $570.00, and a low estimate of $333.00.

This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to ...

Fintel reports that on August 4, 2025, Oppenheimer upgraded their outlook for Alnylam Pharmaceuticals (NasdaqGS:ALNY) from ...

Investors might want to bet on Alnylam Pharmaceuticals (ALNY), as earnings estimates for this company have been showing solid ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $406.0, a high estimate of $550.00, and a low estimate of $333.00. This current average reflects ...

After going through a strategic reset last year that involved pulling its ALS drug off the market, Amylyx Pharmaceuticals has ...

The better-than-expected launch of a rare heart disease drug pushed Alnylam (Nasdaq: ALNY) past the $50 billion market ...